S.C. Agency, a leading creative design agency, announces its successful collaboration with ActivInsights, a pioneering global ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Qorvo stock is soaring Friday after activist investor Starboard Value disclosed a new stake in the Apple supplier. Here's ...

Highlights,Pfizer Inc. plans to reduce its stake in Haleon PLC by selling approximately 700 million shares, representing 7.7% ...

The flu vaccine is generally about 40% effective at completely preventing influenza, according to Blumberg. The flu vaccine ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer ... Law360.com website. GSK's vaccine has just hit the mark in a phase 3 trial, and the ...

In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial ( NCT06712355) evaluating BNT327/PM8002 plus chemotherapy compared to atezolizumab plus chemotherapy in first line ...

This week's anticipated dividend increases feature three companies with an average increase of 8.9% and a median increase of ...

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE ...

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...